| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db8acd71f5994544bda6df3f27a3f51e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4e5a65a7091bbb2d2679d5e0fc4b4cf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-05 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 |
| filingDate |
2019-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f6ec44ab0630cb5b0da9a846ae2ff0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d2dd0ee6c1aeb885667d09a83f71c40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e5d5d7a9c83367c3d68eb5a7c5d686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb58073d92491d3bdf155bd5b49dac2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ebf30541488389a2bce23c0392060cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc4dbd80ac415505f68ea83f8bf7de0a |
| publicationDate |
2021-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021052721-A1 |
| titleOfInvention |
Hepatitis c virus peptide compositions and methods of use thereof |
| abstract |
The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. |
| priorityDate |
2018-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |